Attachment: FORM 8-K


Exhibit 16.1

 

July 7, 2022

 

Securities and Exchange Commission

100 F Street, N.E.

Washington, DC 20549

 

Commissioners:

 

We have read the statements made by First Wave BioPharma, Inc. under Item 4.01 of its Form 8-K dated July 5, 2022. We agree with the statements concerning our Firm in such Form 8-K; we are not in a position to agree or disagree with other statements of First Wave BioPharma, Inc. contained therein.

 

Very truly yours,

 

/s/ Marcum llp

 

Marcum llp

 

 

 

 


fwbi-20220705.xsd
Attachment: XBRL TAXONOMY EXTENSION SCHEMA


fwbi-20220705_lab.xml
Attachment: XBRL TAXONOMY EXTENSION LABEL LINKBASE


fwbi-20220705_pre.xml
Attachment: XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE